Parkview Health Services: Adherence and Persistence in Long-Acting Injectable Treatment for Opioid Use Disorder

This analysis examines adherence and persistence among patients receiving long-acting injectable (LAI) treatments for opioid use disorder (OUD), including Sublocade®, Brixadi®, and Vivitrol®, using Parkview Health Services data from January 2025 through March 2026. Findings demonstrate strong real-world adherence, with 74% of patients achieving at least 80% proportion of days covered (PDC) and 40% reaching 95% PDC, exceeding many previously reported real-world benchmarks. Sustained treatment exposure was associated with reduced overdose risk, lower mortality, fewer emergency department visits and hospitalizations, and improved patient stability. Modeling suggests that high adherence levels may have prevented approximately 591 overdose events and nearly $10 million in acute healthcare costs, reinforcing the clinical, economic, and public health value of LAI therapies as an effective strategy for improving long-term outcomes in OUD management.

Download the full report here.